Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
Allogene Therapeutics (Nasdaq: ALLO) has announced the promotion of Benjamin M. Beneski to Senior Vice President and Chief Technical Officer (CTO). He succeeds Tim Moore, who will step down at the end of February after two years with the company. Beneski, who joined Allogene in 2019, will oversee technical operations and advance the company's allogeneic cell therapy programs.
Beneski's experience includes leading the design and construction of Cell Forge 1, the company's manufacturing facility, and serving as Vice President of Manufacturing and Vice President of Product Development and Manufacturing. His career spans over 20 years in biologics manufacturing, with previous roles at Vir Biotechnology and Amgen.
Allogene Therapeutics (Nasdaq: ALLO) ha annunciato la promozione di Benjamin M. Beneski a Senior Vice President e Chief Technical Officer (CTO). Succede a Tim Moore, che si dimetterà alla fine di febbraio dopo due anni in azienda. Beneski, che è entrato in Allogene nel 2019, supervisionerà le operazioni tecniche e porterà avanti i programmi di terapia cellulare allogenica dell'azienda.
L'esperienza di Beneski include la guida della progettazione e costruzione di Cell Forge 1, l'impianto di produzione dell'azienda, e il ruolo di Vice Presidente della Produzione e Vice Presidente dello Sviluppo e della Produzione del Prodotto. La sua carriera si estende per oltre 20 anni nella produzione di biologici, con ruoli precedenti presso Vir Biotechnology e Amgen.
Allogene Therapeutics (Nasdaq: ALLO) ha anunciado la promoción de Benjamin M. Beneski a Vicepresidente Senior y Director Técnico (CTO). Sucede a Tim Moore, quien renunciará a finales de febrero después de dos años en la empresa. Beneski, quien se unió a Allogene en 2019, supervisará las operaciones técnicas y avanzará en los programas de terapia celular alogénica de la empresa.
La experiencia de Beneski incluye liderar el diseño y la construcción de Cell Forge 1, la instalación de fabricación de la empresa, y haber sido Vicepresidente de Fabricación y Vicepresidente de Desarrollo y Fabricación de Productos. Su carrera abarca más de 20 años en la fabricación de biológicos, con roles previos en Vir Biotechnology y Amgen.
Allogene Therapeutics (Nasdaq: ALLO)는 Benjamin M. Beneski를 수석 부사장 겸 최고 기술 책임자(CTO)로 승진시켰다고 발표했습니다. 그는 회사에서 2년을 보낸 Tim Moore를 대신합니다. 2019년 Allogene에 합류한 Beneski는 기술 운영을 감독하고 회사의 동종 세포 치료 프로그램을 발전시킬 예정입니다.
Beneski의 경험에는 회사의 제조 시설인 Cell Forge 1의 설계 및 건설을 이끌고, 제조 부사장 및 제품 개발 및 제조 부사장으로 활동한 경력이 포함됩니다. 그의 경력은 생물 제제 제조 분야에서 20년 이상을 포괄하며, Vir Biotechnology와 Amgen에서의 이전 역할이 있습니다.
Allogene Therapeutics (Nasdaq: ALLO) a annoncé la promotion de Benjamin M. Beneski au poste de Vice-président senior et directeur technique (CTO). Il succède à Tim Moore, qui démissionnera à la fin du mois de février après deux ans au sein de l'entreprise. Beneski, qui a rejoint Allogene en 2019, supervisera les opérations techniques et fera progresser les programmes de thérapie cellulaire allogénique de l'entreprise.
L'expérience de Beneski comprend la direction de la conception et de la construction de Cell Forge 1, l'installation de fabrication de l'entreprise, ainsi que des rôles de vice-président de la fabrication et de vice-président du développement et de la fabrication de produits. Sa carrière s'étend sur plus de 20 ans dans la fabrication de biologiques, avec des rôles précédents chez Vir Biotechnology et Amgen.
Allogene Therapeutics (Nasdaq: ALLO) hat die Beförderung von Benjamin M. Beneski zum Senior Vice President und Chief Technical Officer (CTO) angekündigt. Er folgt Tim Moore nach, der Ende Februar nach zwei Jahren im Unternehmen zurücktritt. Beneski, der 2019 zu Allogene gekommen ist, wird die technischen Operationen leiten und die Programme zur allogenen Zelltherapie des Unternehmens vorantreiben.
Beneskis Erfahrung umfasst die Leitung des Designs und des Baus von Cell Forge 1, der Produktionsstätte des Unternehmens, sowie die Tätigkeit als Vizepräsident für Herstellung und Vizepräsident für Produktentwicklung und Herstellung. Seine Karriere erstreckt sich über mehr als 20 Jahre in der Biologika-Herstellung, mit vorherigen Positionen bei Vir Biotechnology und Amgen.
- Seamless leadership transition with internal promotion ensuring continuity in technical operations
- Appointment of experienced executive with proven track record in biologics manufacturing
- Maintained stability in manufacturing operations with leadership from Cell Forge 1 facility
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that Benjamin M. Beneski has been promoted to Senior Vice President and Chief Technical Officer (CTO). Mr. Beneski succeeds Tim Moore, who will be stepping down at the end of February after two years with the Company. Mr. Moore’s impactful career spans nearly a decade of collaboration with the broader team, during which he made significant contributions to Allogene and the field of cell and gene therapy.
As CTO, Mr. Beneski will oversee Allogene’s technical operations, leveraging his extensive expertise in biologics manufacturing, process development, and operational leadership to carry on the work of Mr. Moore and further advance the company’s groundbreaking allogeneic cell therapy programs.
"We are delighted to announce Ben's promotion to Chief Technical Officer," said David Chang, M.D., Ph.D., President, CEO, and Co-Founder of Allogene. "His leadership and dedication have been instrumental in shaping our manufacturing strategy and capabilities. Ben’s proven track record of delivering results, creating innovative solutions, and building high-performing teams makes him uniquely qualified to lead our technical operations into the next phase."
Dr. Chang continued, "Many of us at Allogene have had the distinct privilege of working alongside Tim for nearly a decade. He joined us during a crucial time, bringing expertise and leadership that were instrumental in getting us to where we are today. We are deeply grateful for Tim's unwavering commitment, transformative contributions, and exceptional dedication to mentoring and empowering the next generation of leaders. Tim will forever remain a dear friend and an enduring part of Allogene's legacy."
Mr. Beneski joined Allogene in 2019 as Executive Director and Plant Manager, leading the design, construction, and startup of Cell Forge 1, the company’s state-of-the-art manufacturing facility. Over the years, he has held increasingly senior roles, including Vice President of Manufacturing and Vice President of Product Development and Manufacturing. In these roles, he led the development of next-generation platforms, successfully managed internal and external manufacturing networks, and drove key initiatives supporting IND submissions and commercial readiness.
Mr. Beneski’s career spans over two decades in biologics manufacturing and technical operations, including leadership roles at Vir Biotechnology and Amgen. He holds a Master’s in Business Administration from Northeastern University and a Bachelor of Engineering in Chemical Engineering from Stevens Institute of Technology.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “will,” “advance,” “goal,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for treating cancer and autoimmune disease, the ability to advance allogeneic cell therapy programs or develop next generation platforms, or the ability to develop a pipeline of “off-the-shelf” CAR T cell product candidates that deliver readily available cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including, risks and uncertainties related to: our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and whether we will ultimately obtain regulatory approval. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Form 10-Q filed for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be965d76-f1a3-4452-bb4d-9ba99d7b1962
FAQ
Who is the new CTO of Allogene Therapeutics (ALLO) in 2025?
When did Benjamin Beneski join Allogene (ALLO)?
What is Cell Forge 1 at Allogene (ALLO)?
Who is Benjamin Beneski replacing as CTO at Allogene (ALLO)?
